title: The importance of BMI in dosimetry of153Sm-EDTMP bone pain palliation therapy: A Monte Carlo study.
abstract: Using digital phantoms as an atlas compared to acquiring CT data for internal radionuclide dosimetry decreases patient overall radiation dose and reduces the required analysis effort and time for organ segmentation. The drawback is that the phantom may not match exactly with the patient. We assessed the effect of varying BMIs on dosimetry results for a bone pain palliation agent,153Sm-EDTMP. The simulation was done using the GATE Monte Carlo code. Female XCAT phantoms with the following different BMIs were employed: 18.6, 20.8, 22.1, 26.8, 30.3 and 34.7kg/m2. S-factors (mGy/MBq.s) and SAFs (kg-1) were calculated for the dosimetry of the radiation from major source organs including spine, ribs, kidney and bladder into different target organs as well as whole body dosimetry from spine. The differences in dose estimates from different phantoms compared to those from the phantom with BMI of 26.8kg/m2as the reference, were calculated for both gamma and beta radiations. The relative differences (RD) of the S-factors or SAFs from the values of reference phantom were calculated. RDs greater than 10% and 100% were frequent in radiations to organs for photon and beta particles, respectively. The relative differences in whole body SAFs from the reference phantom were 15.4%, 7%, 4.2%, -9.8% and -1.4% for BMIs of 18.6, 20.8, 22.1, 30.3 and 34.7kg/m2, respectively. The differences in whole body S-factors for the phantoms with BMIs of 18.6, 20.8, 22.1, 30.3 and 34.7kg/m2were 39.5%, 19.4%, 8.8%, -7.9% and -4.3%, respectively. The dosimetry of the gamma photons and beta particles changes substantially with the use of phantoms with different BMIs. The change in S-factors is important for dose calculation and can change the prescribed therapeutic dose of153Sm-EDTMP. Thus a phantom with BMI better matched to the patient is suggested for therapeutic purposes where dose estimates closer to those in the actual patient are required.
authors.affiliation: Department of Nuclear Medicine, Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Fallahpoor
authors.affiliation: Department of Nuclear Medicine, Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: meabbasi@tums.ac.ir.
authors.forename: Mehrshad
authors.initials: M
authors.lastname: Abbasi
authors.affiliation: Department of medical physics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
authors.forename: Ali
authors.initials: A
authors.lastname: Asghar Parach
authors.affiliation: Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75235, United Stated.
authors.forename: Faraz
authors.initials: F
authors.lastname: Kalantari
mesh_terms: D015992:Body Mass Index; D001859:Bone Neoplasms / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary; D005260:Female; D006801:Humans; D009010:Monte Carlo Method; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010146:Pain / Q000532:radiotherapy*; D010166:Palliative Care; D019047:Phantoms, Imaging / Q000706:statistics & numerical data; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods* / Q000706:statistics & numerical data; D012493:Samarium / Q000627:therapeutic use*
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012493:Samarium; C000615023:Samarium-153; C061972:samarium Sm-153 lexidronam
keywords: (153)Sm EDTMP; GATE; Internal dosimetry; Monte Carlo; XCAT